QTTB QTTB
Company Profile ↓Company Overview
QTTB (QTTB) is a publicly traded company listed on with a market capitalization of $212.03M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 71.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 33.5%.
Revenue has grown at a 39.1% CAGR over the past five years.
Trades at an undemanding P/E of 6.8.
Maintains a net profit margin of 55.5%.
Carries low leverage with a debt-to-equity ratio of 0.37.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR 39.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.14% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +754.40% |
| 6 Months: | +289.83% |
| 3 Months: | +220.82% |
| 1 Month: | +21.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 71.0%.
- Healthy ROCE of 33.5%.
- Excellent profit margin of 55.5%.
- Compounding revenue at 39.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.13M | 1.40M | 1.60M | 270.00K | 392.00K | 441.00K | 588.00K | 567.00K | 567.00K | 29.30M | 2.19M | 1.68M | 802.00K | 802.00K | 802.00K | 802.00K | 354.00K | 0 | - | - | - | - | 0 | 0 | 0 | 53.74M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.23M | 9.17M | 7.58M | 7.86M | 7.72M |
| Operating Income | -4.69M | -6.04M | -6.66M | -10.70M | -13.42M | -15.63M | -25.12M | -27.97M | -31.29M | -36.49M | -35.70M | -28.27M | -1.11M | -30.55M | -30.66M | -37.62M | -28.31M | -32.86M | -7.37M | -7.28M | -7.80M | -14.84M | -17.92M | -18.81M | - | -12.23M | -9.17M | -7.58M | 45.88M | -7.72M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.11M | -9.10M | -7.00M | 58.02M | -7.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 300.00K | 300.00K | 300.00K | 200.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.03M | -9.49M | -7.39M | 57.73M | -7.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.00K | 0 | 0 | - | - | - |
| Net Income | -5.55M | -6.00M | -6.53M | -10.22M | -12.43M | -14.15M | -23.85M | -26.27M | -29.63M | -35.33M | -35.34M | -28.23M | -1.07M | -30.50M | -30.61M | 92.11M | -29.09M | -33.73M | -6.84M | -5.81M | -14.03M | 1.03M | -16.98M | -17.59M | - | -11.03M | -9.49M | -7.39M | 57.73M | -7.61M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.02 | -0.54 | -0.54 | 1.59 | -0.51 | -0.59 | -19.84 | -16.69 | -40.52 | -6.33 | -1.42 | -1.46 | - | -0.90 | -0.78 | -0.60 | - | -0.54 |
| R&D Expense | 2.80M | 4.06M | 4.95M | 8.00M | 10.29M | 13.39M | 20.54M | 22.83M | 25.69M | 29.31M | 27.47M | 20.42M | 21.75M | 23.70M | 23.99M | 24.27M | 21.07M | 25.85M | 7.91M | 8.02M | 7.46M | 9.84M | 13.41M | 14.35M | - | 7.12M | 5.16M | 3.56M | - | 3.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 5.32M | 1.67M | 2.70M | 33.97M | 6.65M | -6.65M | 0 | 53.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 45.88M | 41.60M | 66.10M | 36.84M |
| Operating Income | -29.66M | -59.93M | -109.94M | -130.26M | -95.95M | -39.23M | -48.26M | -66.10M | 16.90M |
| EBITDA | - | - | - | - | - | -38.85M | -47.76M | -44.50M | 31.31M |
| Interest Expense | - | - | - | - | - | - | - | 1.10M | 1.10M |
| Pretax Income | - | - | - | - | - | -42.75M | -53.42M | -46.09M | 29.82M |
| Tax Provision | - | - | - | - | - | 62.00K | 318.00K | 21.00K | 0 |
| Net Income | -29.99M | -55.58M | -103.92M | -128.69M | -95.76M | -42.81M | -53.74M | -47.73M | 29.82M |
| Diluted EPS | - | - | - | - | -1.73 | -3.59 | -4.51 | -6.58 | 2.42 |
| R&D Expense | 21.38M | 47.95M | 89.40M | 100.39M | 93.08M | 98.35M | 31.73M | 48.14M | 19.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 137.53M | 259.09M | 310.57M | 263.74M | - | 61.77M | 47.06M | 92.33M | 61.78M |
| Current Assets | - | - | - | - | - | - | 46.85M | 28.72M | 81.88M | 55.05M |
| Cash & Equivalents | 11.39M | 51.58M | 38.22M | 53.77M | 217.43M | - | 43.89M | 25.62M | 77.97M | 48.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 1.06M | 755.00K | 555.00K | 5.39M |
| Total Liabilities | - | 39.22M | 62.74M | 52.06M | 67.74M | - | 192.49M | 229.98M | 86.66M | 19.76M |
| Current Liabilities | - | 8.86M | 22.52M | 12.37M | 22.66M | - | 57.87M | 14.11M | 16.46M | 11.35M |
| Long Term Debt | - | - | - | - | - | - | 5.07M | 43.18M | 9.56M | 3.47M |
| Total Debt | - | - | - | - | - | - | 44.73M | 50.84M | 18.90M | 15.34M |
| Total Equity | -9.89M | -39.45M | 196.35M | 258.51M | 196.00M | - | -130.71M | -182.92M | 5.67M | 42.01M |
| Shares Outstanding | - | - | - | - | - | - | 11.93M | 11.93M | 12.20M | 12.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 6.48M | -42.56M | -91.36M | -94.33M | - | -10.96M | -18.68M | -67.72M | -33.54M |
| Investing Cash Flow | -81.53M | -121.79M | -51.80M | 204.90M | - | -2.47M | -5.00K | 19.93M | 7.00M |
| Financing Cash Flow | 115.23M | 150.99M | 158.21M | 53.09M | - | 30.07M | 406.00K | 95.14M | -3.12M |
| Capital Expenditure | -1.96M | -24.94M | -21.83M | -3.73M | -157.00K | -2.48M | -5.00K | -75.00K | - |
| Free Cash Flow | 4.52M | -67.50M | -113.19M | -98.06M | - | -13.44M | -18.68M | -67.79M | -33.54M |
| Net Change in Cash | - | - | - | - | - | 16.65M | -18.28M | 47.35M | -29.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -1,126.0% | -6,599.2% | -4,821.0% | -282.4% | -589.8% | 725.5% | - | 31.5% |
| Net Margin % | - | -1,044.3% | -6,237.5% | -4,762.9% | -281.9% | -643.6% | 808.0% | - | 55.5% |
| ROE % | 76.0% | -28.3% | -40.2% | -65.7% | - | 32.8% | 29.4% | -841.1% | 71.0% |
| ROCE % | -23.0% | -25.3% | -36.9% | -54.0% | - | -1,003.5% | -146.5% | -87.1% | 33.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QTTB
QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month – What’s Driving The Investor Optimism? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNOHJreVhmQW1NeUdySzFvd0hxY3RPdU1jM1NMcU9lMVF1WVJyQWw5WWRRMlB6dVdGOHcyRFpiNmh1Y3k4cnZTSjUydklJREc1c3RNY2NiS3d0bFZuODczQzVBWlhGNVYtdzZqeXYzdFpwSnBMcDRObjFCUkRLRlZ0RjQtakdWTDVsMnVKbU…
In Q32 Bio Trial, 40% Reached 80% Scalp Hair Coverage - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNd1EyRHk2N2R2UjRWLXI4WWNHb1pZaWlDU3hHZDRTRzFWVWMwc1B6Y3dUWXdycE14UlhoaGRoLXV3TEZkOVF1NzZjd2llMl9uUEx1TTRNNHFMWlU1OUItcGhTZko4M3k3bU1MbW9FLWFNZ3NsbTBYSWJwZ3dhTF9iRGJOdld5Rk5tYTRPM0…
Q32 Bio tops estimates as alopecia drug advances toward late-stage trials (QTTB:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPaG1KZUx3dVVXYndteE1vcmY2eFhmdzg3dW96VlVQaTBEanRGcmNZdFUxOU03WS1jblplcFFJYVpybFNySDdxLTA1TkRLakdrLVJydXRNdVVHRVloU0djaGtJOE5EQ2tuNTB1dHZJN2dROWx1dUZuSklkbFZDRlhoT29KYVhUTDFWVWt2OV…
H.C. Wainwright Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxORkNPcFVoaWhOb29iY1gyVGJiVVN2djQ3QWtodkVZNjNyaWJXTUpUVnFqT1BEUjZRYXJCX1pPQmlRbnZjaW95YUM5a1JHTDZleEJlNEVOaHl3VHpEVHRodDNrdk5QT0JxU0M2TUI4ckFPTXpxOU9vVEZHM0dodU5XbjJ1NDl1QUZkSS0xZG…
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQS1doc2lNUk9EWjktN01aSkhKanlCUXRkelgyU01vcnpuQkhKX0Z2cHNieUg2QnRHaTV5ZFc2QXZlZXpnUzQ3cElmV3FmUU9NSkw4MHpxVmRxaWt4U3M0ZFQxZGtFT0dkMzhDZ2VCU2swb2RZYS1HTlJFWEtFcWRHT3ZnZjB1b0o3S1AwSE…
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPWWI3QnZfX1paN2ZQYkpjODVSWG1LZ1MyS004bnNyTG1LaUFOYU1WZTRlSEw4RjNfOVBYWnl1NThsZXJKaER0by0yMUFoV1B5YmFKT1l3X0xVSExUdGhQc2I3a2lVT3ZoRkFfcTBYYUR4dXNJRjliTkxJWUhZbE1Pem0xalpvWFFPbjNLV2…
QTTB — Frequently Asked Questions
What is the current share price of QTTB?
As of 2026-08-05 17:25 PDT, QTTB trades at $16.49 on NASDAQ/NYSE. Its 52-week range is $1.63 to $21.38.
What is the market capitalisation of QTTB?
QTTB has a market capitalisation of $212.03M on NASDAQ/NYSE.
What is the P/E ratio of QTTB?
QTTB trades at a trailing price-to-earnings (P/E) ratio of 6.81. Its price-to-book (P/B) ratio is 5.05.
What is the return on equity (ROE) of QTTB?
QTTB has a return on equity (ROE) of 70.98%. Its return on capital employed (ROCE) is 33.52%.
Is QTTB a good stock to buy?
This page provides a data-driven analysis of QTTB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.